As per the research report, the size of the North America Competent Cells Market is valued at USD 0.70 billion in 2022 and estimated to grow at a CAGR of 10.51%, to reach USD 1.15 billion by 2027 during the forecast period 2022 to 2027.
Advances in molecular engineering, as a result of the advent of new cell technologies in the biotechnology industry, rising public and private sector investments, and the launch of novel product types, various government initiatives & funding for life science research are boosting the North America market's growth. In addition, genetic engineering and biotechnology have broadened the field of healthcare by allowing for the treatment of previously incurable diseases.
The high demand for products developed from recombinant DNA technology drives the competent cells market. They can be used to create a wide range of medicinal products, including vaccinations & the protein treatments. In addition, increasing research and development on DNA technologies in research institutes & product development are expected to boost the market growth.
Furthermore, the demand for advanced products for disease treatment and favorable regulatory rules are boosting market expansion.
Because of the COVID-19 pandemic, there is a greater focus on cell cloning activities such as recombinant protein expression and mutagenesis and an increase in demand for competent cells for creating cloned copies of viral plasmids. The life science business has grown due to continued government funding and academic excellence. Extensive research studies are speeding up the adoption of modern technologies in the study of living organisms, paving the way for creating transformative healthcare using living cells like competent cells.
The high cost of competent cell research and development and the market consolidation of a few key firms are projected to restrict market expansion over a period. In addition, the lack of a well-defined regulatory framework is significantly impeding the inflow of competent cell demand. The competent cells market is expected to face challenges due to a scarcity of experienced people in the forecast term.
This research report on the North America Competent Cells Market has been segmented and sub-segmented into the following categories.
By Type:
By Application:
By End User:
By Country:
Geographically, the North American region holds the most significant share of the global competent cells market because of the increased commercial demand for recombinant products and considerable research efforts in recombinant therapies due to the technological advancements in this region.
The U.S Competent cells market is the most revenue region globally owing to the region's well-established healthcare system, better acceptance of new technology, a surge in non-communicable diseases and related pharmaceutical research and development, an increase in cloning-based research, and the presence of numerous major companies.
The Canada Competent cells market is predicted to grow significantly due to the rise in the biotechnology and pharmaceutical sectors. In addition, an increased inclination toward genomics and proteomics-based research contributes to the market's growth.
Since the COVID-19 pandemic, cell cloning activities like recombinant protein expression and mutagenesis have gotten a lot of attention, and the business is booming. As a result, there has been a significant demand for competent cells capable of producing copies of the SARS-nCoV genome to perform research on it. Furthermore, the rise in demand for novel products and growing nations provide profitable prospects for competent cells market players in the forecast future.
KEY MARKET PLAYERS
Companies playing a dominant role in the North America Competent Cells Market profiled in this report are BioDynamics Laboratory, Inc. (Japan), GCC Biotech (India), SMOBIO Technology (Taiwan), Thermo Fisher Scientific, Inc. (the U.S), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Merck KGaA (Germany), Promega Corporation (U.S.), Bioline (U.K.), Zymo Research (U.S.), are the leaders in the North America Competent Cells market.,
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Chemically
5.1.2 Electrocompetent
5.1.3 Y-o-Y Growth Analysis, By Type
5.1.4 Market Attractiveness Analysis, By Type
5.1.5 Market Share Analysis, ByType
5.2 Application
5.2.1 Cloning
5.2.1.1 Subcloning & Routine Cloning
5.2.1.2 Phage Display Library Construction
5.2.1.3 Toxic/Unstable Dna Cloning
5.2.1.4 High-Throughput Cloning
5.2.2 Protein Expression
5.2.3 Other Applications
5.2.3.1 Mutagenesis
5.2.3.2 Large Plasmid Transformation
5.2.3.4 Single-Stranded Dna Production
5.2.3.5 Lentiviral Vector Production
5.2.7 Y-o-Y Growth Analysis, By Application
5.2.8 Market Attractiveness Analysis, By Application
5.2.9 Market Share Analysis, By Application
5.3 End User
5.3.1 Pharmaceutical Companies
5.3.2 Academia
5.3.3 Y-o-Y Growth Analysis, By EndUser
5.3.4 Market Attractiveness Analysis, By EndUser
5.3.5 Market Share Analysis, By EndUser
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Application
6.1.3.4 By EndUser
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Application
6.1.4.4 By EndUser
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Application
6.1.5.4 By EndUser
6.2 United States
6.3 Canada
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 BioDynamics Laboratory, Inc. (Japan)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GCC Biotech (India)
8.3 SMOBIO Technology (Taiwan)
8.4 Thermo Fisher Scientific, Inc. (U.S)
8.5 QIAGEN N.V. (Germany)
8.6 OriGene Technologies (U.S.)
8.7 Merck KGaA (Germany)
8.8 Promega Corporation (U.S.)
8.9 Bioline (U.K.)
8.10 Zymo Research (U.S.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
